Related Experiment Videos
Future treatment options for Gram-positive infections--looking ahead
1Bristol Centre for Antimicrobial Research & Evaluation, University of Bristol and North Bristol NHS Trust, Department of Medical Microbiology, Southmead Hospital, Bristol, UK.
Summary
New injectable antimicrobials show promise for treating multidrug-resistant Gram-positive infections, particularly Staphylococcus aureus. Drug safety will be crucial for regulatory approval and long-term clinical success.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Multidrug-resistant Gram-positive infections, especially Staphylococcus aureus, pose a significant therapeutic challenge.
- Current management relies heavily on injectable antimicrobials, with ongoing research into novel approaches.
Purpose of the Study:
- To review the current landscape and future prospects of antimicrobial drug development for Gram-positive infections.
- To assess the status of new anti-Gram-positive agents in regulatory review and clinical trials.
Main Methods:
- Review of recently approved and investigational anti-Gram-positive agents.
- Analysis of antibacterial spectra, in vitro potency, bactericidal activity, pharmacokinetics, and safety profiles.
- Assessment of clinical trial data and regulatory status.
Main Results:
- Five new anti-Gram-positive agents have been approved in the EU since 1999.
- Several agents are under review or have completed Phase III trials, demonstrating promising pharmacodynamic properties and clinical efficacy.
- Established safety profiles exist for approved agents.
Conclusions:
- Injectable antimicrobials are the primary focus of current drug development for Gram-positive infections.
- Drug safety is a critical factor influencing regulatory approval and clinical adoption of new antimicrobial agents.
- Future management may incorporate immunotherapies, novel antibiotic targets, topical treatments, and advanced drug delivery systems.
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:27Production of Antibiotics
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...